Retatrutide 10 mg + Cagrilintide 10 mg Bundle

Retatrutide (also referenced in research literature as LY3437943) is a synthetic 39-residue peptide engineered as a unimolecular triagonist of the GIP, GLP-1, and glucagon receptors. It was developed to extend the pharmacology of earlier incretin-based research compounds, including single-agonist GLP-1 analogs and dual GIP/GLP-1 agonists, by adding a third receptor arm: glucagon receptor engagement.

The rationale behind triagonist research is that combined receptor signaling may modulate energy-metabolism research models through complementary pathways. GLP-1 receptor activity contributes to glucose-signaling research and central neuroendocrine-pathway research; GIP receptor activity is associated with insulin-signaling research and lipid-pathway adaptation in adipose research models; glucagon receptor activity is investigated for its association with energy-expenditure research and hepatic lipid-metabolism research.

This positioning at the intersection of three established incretin and metabolic-pathway receptors has made retatrutide an experimental research compound of considerable interest in laboratory research studies of integrated receptor pharmacology, metabolic-pathway crosstalk, and energy-balance research models.

Cagrilintide is a synthetic 37-residue amylin-analog research peptide engineered for extended half-life through C16 fatty-acid acylation. The molecule was developed to overcome the short circulating half-life of native amylin and pramlintide research peptides, enabling once-weekly research dosing schedules in laboratory research studies.

Amylin is an endogenous 37-residue peptide co-secreted with insulin from pancreatic beta-cells in research models. Amylin receptor signaling research is associated with gastric-pathway research, neuroendocrine pathways relevant to energy-balance research, and glucose-signaling research. The development of cagrilintide as a long-acting amylin analog drew on structure-activity research to balance receptor selectivity, solubility, and pharmacokinetic stability (Kruse et al., 2021, Journal of Medicinal Chemistry).

This positioning at the intersection of amylin-pathway research and long-acting peptide engineering has made cagrilintide an experimental research compound of considerable interest in laboratory research studies of amylin receptor pharmacology, combined peptide research alongside GLP-1 receptor agonists, and integrated metabolic-pathway signaling research.

1. GLP-1 Receptor Engagement

Retatrutide engages the GLP-1 receptor, a class B G-protein-coupled receptor expressed across pancreatic, central, and peripheral tissues in research models. GLP-1 receptor signaling research is associated with glucose-dependent insulin-signaling pathways and central neuroendocrine modulation relevant to energy-balance research.

2. GIP Receptor Engagement

Retatrutide also engages the GIP receptor, which is widely expressed in adipose and pancreatic research tissues. GIP receptor signaling is investigated for its role in insulin-signaling research, adipose-pathway adaptation, and lipid-handling research models.

3. Glucagon Receptor Engagement

The glucagon receptor arm distinguishes retatrutide from dual-agonist research compounds. Glucagon receptor signaling is investigated in laboratory research studies for its association with hepatic glucose-output research, lipid-metabolism research, and energy-expenditure research models.

4. Integrated Triagonist Signaling

By interacting with all three receptor systems within a single molecule, retatrutide is investigated as a tool for studying receptor-balance pharmacology, downstream signaling crosstalk, and integrated metabolic-pathway adaptation in research models. Preclinical and laboratory research has characterized its balanced GCGR/GLP-1R activity with relatively higher GIPR activity (Coskun et al., 2022, Cell Metabolism).

Research Applications

Conclusion

Retatrutide represents an experimental research compound class of unimolecular triagonists that engage GIP, GLP-1, and glucagon receptors simultaneously. By integrating three receptor arms within a single peptide, retatrutide supports laboratory research studies of receptor-balance pharmacology and integrated metabolic-pathway signaling, making it a valuable research target for investigations of incretin-pathway research and energy-metabolism research models.

1. Amylin Receptor Engagement

Cagrilintide engages amylin family receptors, which are heterodimers of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Amylin receptor signaling research is associated with gastric-pathway research, central neuroendocrine modulation relevant to energy-balance research, and glucose-signaling research models.

2. Calcitonin Receptor Interaction

Cagrilintide also engages the calcitonin receptor directly, which is investigated in research models for its role in bone-remodeling research and broader neuroendocrine-pathway research. Structural research has characterized cagrilintide binding across calcitonin and amylin receptor subtypes (Kruse et al., 2021, Journal of Medicinal Chemistry).

3. C16 Fatty-Acid Acylation

The C16 fatty-acid side chain extends the half-life of cagrilintide in research models by promoting reversible albumin binding. This enables receptor-pharmacology research at extended timepoints and supports laboratory research studies that examine long-acting amylin receptor engagement.

4. Combined Peptide Research Models

Cagrilintide is frequently investigated in combined research models alongside GLP-1 receptor agonist peptides such as semaglutide. In these laboratory research studies, dual amylin and GLP-1 receptor engagement is studied as an integrated metabolic-pathway research model, distinct from selective single-receptor agonism.

Research Applications

Conclusion

Cagrilintide represents an experimental research compound class of long-acting amylin analogs engineered through fatty-acid acylation for extended half-life in research models. By engaging amylin and calcitonin receptor subtypes, cagrilintide supports laboratory research studies of amylin receptor pharmacology and combined peptide research models, making it a valuable research target for investigations of amylin-pathway research and integrated metabolic-pathway signaling research.